BackBicara Therapeutics Common Stock Overview

Bicara Therapeutics Common Stock Other Current Assets

Bicara Therapeutics Common Stock's other current assets is $5.2M.

Get informed when a big investor buys or sells

+ Follow
Other Current Assets
$5.16M
40.59% YoYΔ $-3.53M vs prior year quarter

Peer average

Loading

Bicara Therapeutics Common Stock Other Current Assets History

Loading

Bicara Therapeutics Common Stock vs. peers: Other Current Assets Comparison

Loading

Bicara Therapeutics Common Stock Other Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Bicara Therapeutics Common Stock (BCAX) FAQ

Bicara Therapeutics Common Stock (BCAX) currently reports a other current assets of $5.2M as of March 2026. That compares with $8.7M in the prior-year period — down 40.6% year over year. Use the charts on this page to explore Bicara Therapeutics Common Stock's other current assets history and peer comparisons.

Bicara Therapeutics Common Stock's other current assets decreased from $8.7M to $5.2M — a 40.6% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Bicara Therapeutics Common Stock reported $5.2M in other current assets as of March 2026. That compares with $8.7M in the prior-year period — down 40.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current assets of $5.2M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Bicara Therapeutics Common Stock, and consider following BCAX for alerts when major investors trade the stock.

Bicara Therapeutics Common Stock is classified in the Healthcare sector. On other current assets, it currently shows $5.2M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BCAX with unrelated industries.